ArticleNPJ vaccines2025
Gut microbiota modulate immune responses to orally and parenterally administered rotavirus in mice.
Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines.Journal of microbiology and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Rotavirus (RV) remains a significant cause of infantile morbidity and mortality, while oral RV vaccines offer inconsistent protection. This study investigates whether gut microbiota influence immune responses to orally and intramuscularly (IM) administered RV strains. Using murine models, we identified microbiota constituents, including segmented filamentous bacteria, reducing oral RV infection and RV antibody generation. Such blockade of RV-induced responses was associated with elevated expression of intestinal Reg3β and Reg3γ and was recapitulated by intraperitoneal administration of cognate recombinant proteins. IM administration following oral RV inoculations enhanced antibody production and defense against RV challenge. We further showed microbiota composition also influenced the efficacy of a single IM RV inoculation. Antibiotic-induced microbiota depletion boosted IM RV efficacy in poorly responding animals. Such enhancement of IM RV-induced immunity appeared to be associated with increased expression of serum RANTES and Eotaxin. The phenotype was recapitulated by directly adjuvating these chemokines to the IM inoculum.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.